Vandenhende F - Search Results

1

On the joint analysis of longitudinal responses and early discontinuation in randomized trials.

Vandenhende F, Lambert P. Vandenhende F, et al. J Biopharm Stat. 2002 Nov;12(4):425-40. doi: 10.1081/BIP-120016228. J Biopharm Stat. 2002. PMID: 12477067 Free article.

2

A copula-based model for multivariate non-normal longitudinal data: analysis of a dose titration safety study on a new antidepressant.

Lambert P, Vandenhende F. Lambert P, et al. Among authors: vandenhende f. Stat Med. 2002 Nov 15;21(21):3197-217. doi: 10.1002/sim.1249. Stat Med. 2002. PMID: 12375299 Free article.

3

Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.

Jullion A, Lambert P, Beck B, Vandenhende F. Jullion A, et al. Among authors: vandenhende f. Pharm Stat. 2009 Apr-Jun;8(2):98-112. doi: 10.1002/pst.336. Pharm Stat. 2009. PMID: 18481279

4

Bayesian hierarchical modeling of receptor occupancy in PET trials.

Vandenhende F, Renard D, Nie Y, Kumar A, Miller J, Tauscher J, Witcher J, Zhou Y, Wong DF. Vandenhende F, et al. J Biopharm Stat. 2008;18(2):256-72. doi: 10.1080/10543400701697158. J Biopharm Stat. 2008. PMID: 18327720

5

Joint detection of important biomarkers and optimal dose-response model using penalties.

Vandenhende F, Eilers P, Ledent E, Renard D, Tibaldi F. Vandenhende F, et al. Stat Med. 2007 Nov 30;26(27):4876-88. doi: 10.1002/sim.2960. Stat Med. 2007. PMID: 17579922

6

Construction of an optimal destructive sampling design for noncompartmental AUC estimation.

Vandenhende F, Comblain M, Delsemme MH, Dewe W, Hoffman WP, Boulanger B. Vandenhende F, et al. J Pharmacokinet Biopharm. 1999 Apr;27(2):191-212. doi: 10.1023/a:1020606006936. J Pharmacokinet Biopharm. 1999. PMID: 10567955

7

Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.

Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, Hirth C, Potter WZ. Chalon SA, et al. Neuropsychopharmacology. 2003 Sep;28(9):1685-93. doi: 10.1038/sj.npp.1300209. Epub 2003 May 28. Neuropsychopharmacology. 2003. PMID: 12784100 Clinical Trial.

8

Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050.

Naganawa M, Dickinson GL, Zheng MQ, Henry S, Vandenhende F, Witcher J, Bell R, Nabulsi N, Lin SF, Ropchan J, Neumeister A, Ranganathan M, Tauscher J, Huang Y, Carson RE. Naganawa M, et al. Among authors: vandenhende f. J Pharmacol Exp Ther. 2016 Feb;356(2):260-6. doi: 10.1124/jpet.115.229278. Epub 2015 Dec 1. J Pharmacol Exp Ther. 2016. PMID: 26628406 Free PMC article.

9

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.

Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, Gehlert DR, Marek G. Tauscher J, et al. Among authors: vandenhende f. Eur Neuropsychopharmacol. 2010 Feb;20(2):80-7. doi: 10.1016/j.euroneuro.2009.10.005. Epub 2009 Dec 16. Eur Neuropsychopharmacol. 2010. PMID: 20018493 Clinical Trial.

10

Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Seneca N, Gulyás B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis RB, Halldin C. Seneca N, et al. Among authors: vandenhende f. Psychopharmacology (Berl). 2006 Sep;188(1):119-27. doi: 10.1007/s00213-006-0483-3. Epub 2006 Aug 4. Psychopharmacology (Berl). 2006. PMID: 16896954

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters